ventricular remodelling. These findings require further validation before clinical translation.

**Rationale** The novel anti-diabetic agents, vildagliptin and sitagliptin, reduce blood glucose by augmenting endogenous levels of glucagon-like peptide (GLP-1), a substance which confers cardioprotection. They do this by inhibiting dipeptidyl peptidase (DPP) IV, the enzyme responsible for breaking down GLP-1. We hypothesised that DPP IV inhibitors might have cardioprotective effects.

**Methodology** Sprague-Dawley rats were given vildagliptin (oral gavage, 20 mg/kg/day), sitagliptin (oral gavage, 100 mg/kg/day), or control for 2 weeks. Excised hearts were then mounted on a Langendorff apparatus and perfused with buffer containing either 5 mmol/l or 11 mmol/l glucose and subjected to 35 min ischaemia/120 min reperfusion.

**Results** Vildagliptin pretreatment reduced myocardial infarct size in hearts perfused with buffer containing 11 mmol/l of glucose (34.4%±4.1% with vildagliptin vs 52.9%±5.2% with control; p<0.05: N>5/group) but not 5 mmol/l glucose (53.2%±4.8% with vildagliptin vs 52.6%±7.2% with control; p>0.05: N>5/group). The infarct-limiting effects were abolished in the presence of exendin9-39 (a GLP-1 receptor antagonist) and H-89 (a PKA antagonist) (61.5%±3.3% with vildagliptin+exendin9-39 and 59.4%±2.1% with vildagliptin+H-89 vs 35.0%±5.0% with vildagliptin+vehicle: p<0.05: N>5/group). Similarly, sitagliptin pretreatment reduced myocardial infarct size in hearts perfused with buffer containing 11 mmol/l of glucose (29.5%±5.1% with sitagliptin vs 52.9%±5.2% with control; p<0.05: N>5/group) but not 5 mmol/l glucose (44.4%±8.3% with sitagliptin vs 52.6%±7.2% with control; p>0.05: N>5/group). Again, the infarct-limiting effects were abolished in the presence of exendin9-39 (65.6%±5.5% with sitagliptin+exendin9-39 vs 30.1%±3.4% with sitagliptin+vehicle; p<0.05: N>5/group).

**Conclusions** Chronic treatment with the DPP-IV inhibitors reduced myocardial infarction via the GLP-1 receptor pathway and may also involve the PKA signalling pathway. Interestingly, this effect appears to be dependent on the blood glucose levels.

**Methodology** We dissected the mechanism of M-haem differentiation by microarray, computational biology and gene manipulation in human primary macrophages and human coronary lesions.

**Results** Microarray analysis showed that M-haem cells were distinct from conventional M1 or M2 subsets. Using computational biology, we identified a simple transcriptional network motif with activating transcription factor 1 (ATF1) as a hub co-inducing HO1, SOCS1 and NR1H2 (LXR-α). Silencing RNA experiments showed that ATF1 induction was required for haem to upregulate HO-1 SOCS1 and NR1H2. Luciferase analysis confirmed that ATF1 transcriptionally activated both HO-1 and LXR. Luciferase deletion mutants indicated that the key ATF1-site in the HO-1 enhancer was distal (~2.9 kb to −4.9 kb). Binding experiments showed that ATF1 bound to this sequence. ATF1 overexpression in human macrophages conferred the characteristics of M-haem cells, including co-induction of HO-1, NR1H2, resistance to foam cell formation, increased survival and anti-oxidant protection.

**Conclusions** Our data define the molecular basis of the differentiation of M-haem, a novel atheroprotective macrophage subset. Our data indicate that redirection of macrophage phenotype in atherosclerosis progression is a modality appropriate for therapeutic development.

**Acknowledgements** We thank BHF for support; Y Tsuji, A Agarwal and P Tontonoz for plasmids.

**Rationale** Monocytes entering tissues, including advanced atherosclerotic plaques, rapidly mature and adapt to their new micro-environment. Intraplaque haemorrhage promotes human atherosclerosis progression and destabilisation via a dual metabolic challenge: cholesterol-enriched erythrocyte membranes and haem. In human coronary culprit lesions, we recently described a novel macrophage subset (M-haem) with atheroprotective properties (IL-10/high HO1/high CD163/high HLA-DR-low MPO-low Sketo-Guanosineline).

**Methodology** We quantified the common MtDNA deletion (4977 bp), previously documented as a sign of plaque instability, using quantitative PCR (qPCR) in human carotid plaques (n=10) or normal carotids (n=7). DNA damage and DDR markers were examined in primary VSMCs of young (mean age 23 years) and older (mean age 60 years) patients using the COMET assay and immunocytochemistry for pATM and pH2AX increase in vascular smooth muscle cells (VSMCs) with increasing disease severity, the effects of cellular ageing on DDR markers are unknown.

**Results** The common mitochondrial deletion increased 1.25-fold in the plaques compared with the normal vessels (p=0.04). In addition, sequencing identified a novel 5031 bp deletion variant, also 1.25-fold higher in the plaques. VSMCs from older patients had increased DNA damage on COMET assay (p<0.0001) and greater abundance of DDR foci (p<0.0001) than young patients, both basally and after treatment with the hydrogen peroxide analogue t-BfH.

**Conclusions** MtDNA damage, manifested as both increased levels of the common and a novel MtDNA deletion, increase in atherosclerosis. VSMC ageing is associated with increased nuclear DNA damage and DDR markers, implying that ageing compromises their ability to repair both nuclear and mtDNA damage may promote premature senescence and atherosclerosis.